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Abstract 
Introduction: -synuclein-induced degeneration of dopaminergic neurons has been proposed 
to be central to the early progression of Parkinson’s disease. This highlights the need to identify 
factors that are neuroprotective or neuroregenerative against -synuclein-induced 
degeneration. Due to their potent neurotrophic effects on nigrostriatal dopaminergic neurons, 
we hypothesized that members of the bone morphogenetic protein (BMP) family have potential 
to protect these cells against -synuclein.  
Methods: To identify the most relevant BMP ligands, we used unbiased gene co-expression 
analysis to identify all BMP family members having a significant positive correlation with five 
markers of dopaminergic neurons in the human substantia nigra (SN).We then tested the ability 
of lead BMPs to promote neurite growth in SH-SY5Y cells and in primary cultures of ventral 
mesencephalon (VM) dopaminergic neurons, treated with either 6-OHDA or MPP+, or 
overexpressing wild-type or A53T -synuclein.  
Results: Only the expression of BMP2 was found to be significantly correlated with multiple 
dopaminergic markers in the SN. We found that BMP2 treatment promoted neurite growth in 
SH-SY5Y cells and in dopaminergic neurons. Moreover, BMP2 treatment promoted neurite 
growth in both SH-SY5Y cells and VM neurons, treated with the neurotoxins 6-OHDA or 
MPP+. Furthermore, BMP2 promoted neurite growth in cells overexpressing wild-type or  
A53T--synuclein.  
Conclusion: These findings are important given that clinical trials of two neurotrophic factors, 
GDNF and neurturin, have failed to meet their primary endpoints. Our findings are a key first 
step in rationalising the further study of BMP2 as a potential neurotrophic factor in -
synuclein-based translational models of Parkinson’s disease. 
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Introduction 
The degeneration of midbrain dopaminergic (mDA) neurons leading to the loss of striatal 
innervation is central to the progression of Parkinson’s disease (PD) (1). -synuclein has been 
linked to PD since a number of mutations, such as the A30P (2) or A53T mutation in SNCA 
(3), as well as triplications (4) or duplications (5) of SNCA, are associated with autosomal 
dominant PD, while SNCA is also a susceptibility gene for sporadic PD (6). In addition,  -
synuclein is the main component of Lewy bodies and Lewy neurites, which are pathological 
hallmarks of PD (7). Overexpression of α-synuclein in individual cultured mDA neurons has 
been shown to reduce neurite growth (8). This is also supported by the reduced connectivity 
and spine formation (9), and decreased neurite length and axonal degeneration (10), found in 
iPSC-derived neurons with SNCA triplication. Moreover iPSC-derived mDA neurons carrying 
the A53T mutation also develop neurite degeneration (11). These studies show that -synuclein 
can lead to axonal and somal degeneration and highlight the need to identify factors that can 
promote mDA neurite growth in neurons carrying an -synuclein load.  
Bone morphogenetic proteins (BMPs) are a group of 15 structurally-related proteins 
that are members of the transforming growth factor (TGF)- superfamily of ligands (12). The 
BMP receptors (BMPRs) (BMPR2 with BMPR1A or BMPR1B) are expressed in embryonic 
and adult rat mDA neurons (13). Adult male BMPR2 dominant-negative mice display an 
almost complete loss (~90%) of striatal innervation, with reduced locomotor activity (14).  
Previous studies have shown that BMP treatment increases mDA neuron number in midbrain 
cultures in vitro (15, 16). Additionally, BMP treatment, or overexpression of a constitutively-
active BMPR1B, promotes neurite growth in SH-SY5Y cells (17), and in primary cultures of 
mDA neurons through the canonical Smad signalling pathway (12, 13, 17, 18). Moreover, 
knockdown of a negative regulator of BMP-Smad signalling during development promotes 
mDA neurite growth and leads to dopaminergic hyperinnervation of the striatum (19). 
However, the expression profiles of individual BMPs in mDA neurons are unknown, as is 
information on the effects of BMPs on neurite growth in cells overexpressing -synuclein. 
Here we show that of all BMPs, only transcripts for BMP2 and the BMPRs are co-
expressed with transcripts for multiple markers of mDA neurons in the human SN. 
Additionally, we show that BMP2 promotes neurite growth and protects against neurotoxin-
induced and wild-type- and A53T--synuclein-induced neurite degeneration in SH-SY5Y cells 
and in primary cultures of mDA neurons. These findings are an important step in rationalizing 
the further study of BMP2 in neurotrophic factor therapy for PD. 
Materials and Methods  
Gene expression analysis of the human SN 
Human SN gene expression data from healthy controls (GSE:60863) (20) and age-matched 
control and PD patients (GSE:49036) (21) were analysed separately using the R2: Genomics 
Analysis and Visualization Platform (http://r2.amc.nl). Pearson correlation analysis with a false 
discovery rate (FDR) multiple testing correction was used to identify all genes that were co-
expressed with five dopaminergic neuronal markers: ALDH1A1, NR4A2, KCNJ6, TH and 
LMX1B in the SN, and four markers enriched in Purkinje cells in the cerebellum: PDE1A1, 
CBLN1, PDE9A, CALB1 (GSE:60863). All gene expression data are presented as log2 
expression values. Differences in expression were determined using one-way ANOVA with 
post hoc Tukey’s test. 
 
Cell culture  
SH-SY5Y cells and embryonic day (E) 14 rat VM were cultured as previously described (13), 
under license with full ethical approval. Cultures were treated with 50ng/ml recombinant 
human (rh)BMP2 (Gibco), 6-OHDA (0-15µM) (Sigma), or MPP+ (0-1mM) (Sigma), unless 
otherwise indicated. For transfection experiments, SH-SY5Y cells and E14 VM cultures were 
transfected with 0.5-1µg of plasmid DNA using the TransIT-X2® Dynamic Delivery System 
(Mirus Bio) according to the manufacturer’s instructions. SH-SY5Y cells were seeded at a 
density of 2.5x104 cells per well and allowed to reach ≥80% confluency prior to transfection. 
E14 VM cultures were seeded at a density of 1.5x105 cells per well. The TransIT-X2:DNA 
complex was prepared according to the manufacturer’s specifications using serum-free 
medium, TransIT-X2 reagent and 0.5-1µg/µl stock of control EGFP plasmid or EGFP--
synuclein-Wild Type (WT) or EGFP--synuclein-A53T plasmids. These were a kind gift from 
David Rubinsztein (Addgene plasmid #40823) (22). The transfection efficiency for SH-SY5Y 
cells and E14 VM cells was 31% and 3%, respectively. 
 
Western Blotting  
Western blotting was carried out as previously described (19). Cells were lysed in RIPA buffer 
and insoluble debris was removed via centrifugation. 28µg of protein was run on a 12% SDS-
PAGE gel and transferred onto polyvinyl difluoride (PVDF) membranes. The membranes were 
incubated with primary antibodies against α-synuclein (1:5000, Merck Millipore) and GAPDH 
(1:1000, SCBT) overnight shaking at 4°C, then washed, incubated with horseradish 
peroxidase-labelled anti-mouse IgG (1:5000, Invitrogen), washed and developed using the 
Pierce™ ECL kit (Thermo Scientific). 
 
Immunocytochemistry  
SH-SY5Y cells were fixed in 4% paraformaldehyde (PFA; Sigma) and E14 VM cultures were 
fixed in ice-cold methanol or 4% PFA for 15 min at room temperature (RT). Cells were washed 
three times for 5 min per wash in 0.02% TritonX-100 (Sigma) in 10mM phosphate buffered 
saline (PBS-T), before being blocked in 5% bovine serum albumin (BSA) in 10mM PBS-T for 
1 h at RT, then incubated overnight at 4°C in tyrosine hydroxylase (TH) (1:2000, Merck 
Millipore; Catalogue number: 36-008) or α-synuclein (SNCA) (1:2000, Merck Millipore; 
Catalogue number: AB152) diluted in 1% BSA in 10mM PBS-T. Following three 5-min 
washes in PBS-T, cells were incubated in the appropriate Alexa Fluor 488- or 594- conjugated 
secondary antibodies (1:500; Invitrogen) diluted in 1% BSA in 10mM PBS-T, for 2 h. 
Following washes in PBS-T, cells were counterstained with DAPI (1:3000; Sigma) and imaged 
using an Olympus IX71.  
 
Assessment of cellular morphology 
To assess cellular morphology, the lengths of 5 randomly-selected neurites were measured in 
no less than 15 randomly-selected fields per N, resulting in at least 225 neurites analysed per 
experiment. To assess somal area, the somal sizes of 5 randomly-selected cells were measured 
in 15 randomly-selected fields per N, resulting in 225 cells analysed per experiment. To 
determine the number of TH positive (TH+) cells, TH and DAPI counts were completed in 15 
randomly-selected fields and the numbers of TH+ cells were expressed as percentages of the 
total DAPI-stained cells. All experiments were repeated at least 3 times and all analyses were 
performed using Image J software.  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 6 (©2018 GraphPad Software, CA 
USA).  Unpaired student’s t-test or one-way ANOVA with post hoc Dunnett’s or Tukey’s test 
were used as indicated to determine significant differences between groups. Results were 
deemed to be significant when p < 0.05. All cell data are presented as mean ± SEM.  
 
 
Results 
Co-expression analysis of the human SN identifies an association between BMPs/BMPRs 
and markers of mDA neurons.  
We first conducted an unbiased co-expression analysis to identify all genes that were co-
expressed with five markers of mDA neurons in the human SN: ALDH1A1, NR4A2/Nurr1,  
KCNJ6/Girk2, TH and LMX1B (Fig. 1a, b) (20).   These analyses revealed significant positive 
correlations only for specific ligands and receptors of the BMP subfamily, namely BMP2, 
BMPR2, BMPR1A and BMPR1B, from the lists of co-expressed genes (Fig. 1b -f). While all of 
the BMPRs were positively correlated with four markers of Purkinje neurons in the human 
cerebellum (PDE1A, CBLN1, PDE9A, CALB1), BMP2 was not (Fig. 1g). BMP2 was also 
expressed at significantly higher levels in the SN than in the putamen or cerebellum (Fig. 1h). 
We next analysed gene expression data from age- and gender-matched samples in GSE:49036 
(21) to examine BMP2 and BMPR expression in the SN of patients at distinct stages of PD. 
These analyses showed a significant downregulation of BMP2 in the SN of PD patients at Braak 
stage 5/6 compared to controls (Fig. 1i), while no significant differences were observed for 
BMPR1B (data not shown) or BMPR2 (Fig. 1j). These data suggest that BMP2-BMPR 
signalling may play a functional role in mDA neurons in the human SN.  
 
BMP2 promotes neurite growth in 6-OHDA- and MPP+--treated, and WT--synuclein- 
and A53T--synuclein-overexpressing, SH-SY5Y cells. 
We next determined that 72h treatment with 1mM MPP+ or 15µM 6-OHDA had a significant 
detrimental effect on neurite length in SH-SY5Y cells (Fig. 2a, b). To determine if rhBMP2 
treatment could promote neurite growth in cells treated with 6-OHDA or MPP+, SH-SH5Y 
cells were treated with 50 ng/ml rhBMP2 and cultured with or without either neurotoxin for 
72h. Here, rhBMP2 promoted neurite growth in cells treated with either 6-OHDA or MPP+, 
both of which had a detrimental effect on neurite growth in SH-SY5Y cells (Fig. 2c, d). To 
investigate if rhBMP2 could promote neurite growth in cells with a PD-causing WT- or A53T-
-synuclein overload, SH-SH5Y cells were transfected with a control-GFP, a WT--
synuclein-GFP or an A53T--synuclein-GFP overexpression plasmid. Western blotting and 
immunocytochemistry revealed strong expression of -synuclein in cells transfected with -
synuclein-GFP (Fig. 2e, f).  Quantification of GFP-positive neurites showed that both WT- and 
A53T--synuclein overexpression induced decreases in neurite length compared to controls (p 
< 0.01) (Fig. 2g, h). However, rhBMP2 treatment was found to promote neurite growth in both 
WT- and A53T--synuclein-overexpressing cells (Fig. 2g, h).  
 
rhBMP2 protects cultured midbrain dopaminergic neurons against 6-OHDA and MPP+. 
As SH-SY5Y cells are catecholaminergic and do not recapitulate all the features of mDA 
neurons, we next examined the effects of rhBMP2 in primary cultures from E14 rat VM. We 
first determined that 72h treatment with 5µM MPP+ or 6-OHDA had a significant detrimental 
effect on TH+ mDA neurite length (Fig. 3a, b).  rhBMP2 treatment induced significant increases 
in mDA neurite growth, even in those cultures treated with 6-OHDA or MPP+ (Fig. 3c, d). We 
then examined the effect of MPP+ and 6-OHDA on somal area and found a reduction in somal 
size which was not seen in cultures treated with rhBMP2 (Fig. 3e). We also assessed cell 
viability and found that both neurotoxins caused a significant decrease in the number of TH+ 
neurons, which was partially rescued by rhBMP2 (Fig 3f, h), while the total cell number 
remained unaffected (Fig. 3g), indicating a partial neuroprotective effect of rhBMP2. These 
data show that rhBMP2 can promote neurite growth and partially protect primary mDA neurons 
against 6-OHDA- and MPP+-induced degeneration.  
 
rhBMP2 promotes neurite growth in WT--synuclein- and A53T--synuclein- 
overexpressing cultured midbrain dopaminergic neurons. 
To investigate if rhBMP2 could also promote neurite growth in mDA neurons overexpressing 
WT- or A53T--synuclein, E14 rat VM cultures were transfected with both WT--synuclein-
GFP and A53T--synuclein-GFP overexpression plasmids, or with a control-GFP plasmid. 
Immunocytochemistry (Fig. 4a) and subsequent quantification of -synuclein staining (given 
the transfection efficiency was not sufficient for western blotting) showed that E14 VM 
cultures transfected with either the WT--synuclein-GFP or A53T--synuclein-GFP plasmid 
showed strong expression of -synuclein compared to cells transfected with the control 
plasmid (Fig. 4b) . While the overexpression of WT--synuclein-GFP or A53T--synuclein 
had no effect on somal area compared to the control-GFP group (Fig. 4c), both WT--
synuclein-GFP and A53T--synuclein-GFP resulted in a significant decrease in neurite length 
compared to controls (p < 0.001) (Fig. 4d, e).  In contrast, WT--synuclein-GFP or A53T--
synuclein-GFP expressing cells that were also treated with rhBMP2 were not significantly 
different from the controls. These data show that WT- or A53T--synuclein reduced neurite 
growth without affecting somal area, and that rhBMP2 can promote neurite growth in cultured 
mDA neurons overexpressing WT- or A53T--synuclein.  
 
Discussion 
In the present study, we have shown that the expression of BMP2 and its receptors, 
BMPR1A, BMPR1B and BMPR2, is positively correlated with five key markers of 
dopaminergic function in the human SN, suggesting a functional relationship between the BMP 
pathway and mDA neurons. We have also shown that BMP2 is highly expressed in the SN 
compared to the putamen or indeed the cerebellum, an area known to be particularly responsive 
to BMPs (23). In agreement with this, previous studies have shown the expression of transcripts 
for BMP2, BMPR1B and BMPR2 receptors in the rat midbrain from E12, a period where 
neurotrophic support is critical, prior to target innervation (13). Furthermore, we have 
identified that BMP2 expression is significantly downregulated in the SN in PD patients at 
Braak stage 5/6, while there are no significant changes in the expression of its receptors. The 
findings of these studies suggest that endogenous BMP signalling, perhaps mediated by BMP2, 
may promote mDA neuronal survival and/or maintain mDA axonal integrity in the adult brain. 
 Using SH-SY5Y cells as an initial cellular model, we examined the functional role of 
BMP2 and found that rhBMP2 exerts a concentration-dependent effect on neurite growth (data 
not shown). In support of this, a number of previous studies have shown that rhBMP2 can 
promote survival and growth in rodent neurons (for review see ref (12)). In addition, we also 
found that rhBMP2 promoted neurite growth against the neuritotoxic effects of two well-
established dopaminergic neurotoxins, MPP+ and 6-OHDA. We then found that the 
overexpression of WT- and A53T--synuclein-GFP in SH-SY5Y cells caused a significant 
decrease in neurite length, which was not seen when co-treated with rhBMP2. However, while 
SH-SY5Y cells are widely-used as an in vitro model of mDA neurons, they are ultimately 
catecholaminergic cells and thus do not replicate all of the features of mDA neurons. To address 
this, we used primary cultures of E14 rat VM and found that rhBMP2 treatment protected mDA 
neurons against MPP+- and 6-OHDA-induced axonal degeneration. Furthermore, we have 
shown that MPP+ causes a reduction to cell soma size, and that both MPP+ and 6-OHDA reduce 
numbers of TH+ neurons, which is partially protected by rhBMP2. In support of our findings, 
rhBMP2-treatment  has also been shown to increase the survival of transplanted E14 VM mDA 
neurons and to decrease motor deficits, in 6-OHDA-lesioned rat models of PD (24). 
Collectively, these data show that rhBMP2 can protect mDA neurons against neurotoxin-
induced injury and thus may have significant potential as a neurotrophic factor for use in PD 
therapy. 
While MPP+ and 6-OHDA are very useful neurotoxins for modelling PD, they do not 
mimic the α-synuclein accumulation that is central to disease progression (25). We therefore 
overexpressed WT- and A53T-α-synuclein in E14 VM cultures and found a decrease in neurite 
length, in agreement with a previous study using E14 rat mDA neurons (8). Here, we found 
that rhBMP2 could promote neurite growth against this α-synuclein-induced axonal 
degeneration. In addition, while both WT- and A53T- α-synuclein had significant effects on 
neurite length, neither WT- or A53T-α-synuclein had an effect on somal size, which is in 
agreement with a previous study (8). This is significant as it is possible that the degenerative 
aetiology of PD may occur at both somal and axon levels (26). Indeed, there have been several 
studies describing axonal degeneration using induced pluripotent stem cell (iPSC)-derived 
mDA neurons isolated from patients with PD. Specifically, iPSCs derived from PD patients 
with SNCA triplications displayed decreased neuronal differentiation, activity and neurite 
outgrowth compared to control iPSCs (27), as well as atypical neurite length and axonal 
fragmentation (10). Additionally, it has also been shown that PD patient iPSC-derived mDA 
neurons display phenotypic characteristics of PD, including Lewy-like neurites comprised of 
pathological α-synuclein, protein aggregation, atypical neurite outgrowth, and fragmented 
axons containing swollen varicosities of α-synuclein or Tau, and have a reduced capability to 
form synapses (11). These data agree with previous in vivo studies showing that transgenic 
mice expressing human α-synuclein develop synaptic dysfunction in striatal DA terminals and 
display an age-dependent reduction in DA release (28, 29). Therefore, given this mounting 
evidence in support of the role of α-synuclein in axonal degeneration in PD, it is important to 
identify neurotrophic factors that can protect against α-synuclein-induced axonal degeneration.  
In summary, we report that BMP2 is co-expressed with mDA neuronal markers in the human 
SN and is downregulated in PD, and that treatment with rhBMP2 can promote mDA neurite 
growth and protect against neurotoxin- and α-synuclein-induced degeneration. These findings 
are important given that clinical trials of two dopaminergic neurotrophic factors, GDNF and 
neurturin, in PD patients have failed to meet their primary endpoints (30). In light of this, the 
findings in our study are an important first step in rationalising the further study of rhBMP2 as 
a potential neuroprotective therapy using -synuclein-based translational models of PD. 
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Figures and Figure Legends  
 
 
Figure 1: BMP2-BMPRs are co-expressed with mDA neuron markers in the human SN.  
(a, b) Pearson correlation analysis showing the r values and false discovery rate (FDR)-
corrected p-values (in parentheses) from the SN (n=99). (c-f) Graphs showing the correlation 
between BMPR2, BMPR1B, BMPR1A, BMP2 and ALDH1A1 expression in the SN. All data 
are 2log expression values. (g) Results of the Pearson correlation analysis showing the r values 
and FDR-corrected p-values (in parentheses) of the correlation of BMPR2, BMPR1B, BMPR1A 
and BMP2 with four Purkinje neuron markers. (h) Box plot showing BMP2 expression in the 
human SN (n=99), putamen (n = 121) and cerebellum (n = 121) (*** p < 0.001 and ### p < 
0.001 vs. SN).  (i, j) 2log expression values of (i) BMP2 and (j) BMPR2 in the SN of PD at 
distinct Braak stages of PD, and in age-matched controls (*p < 0.05 vs. Control). (h-i) One-
way ANOVA with post-hoc Tukey’s test. Raw data was obtained from (b - h) GSE:60863 and 
(i, j) GSE:49036 and analysed using the R2: Genomics analysis and visualisation platform 
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).  
 
 
Figure 2: rhBMP2 promotes neurite growth in MPP+-treated, 6-OHDA-treated and 
A53T -synuclein-overexpressing SH-SY5Y cells.    
(a, b) Total neurite length of SH-SY5Y cells following 72h treatment with either (a) MPP+ or 
(b) 6-OHDA, at the concentrations indicated. (c) Total neurite length and (d) representative 
photomicrographs of SH-SY5Y cells treated with 50ng/ml rhBMP2 and cultured with or 
without 1mM MPP+ or 15μM 6-OHDA for 72 h. Scale bar = 100μm. (e) Representative images 
of SH-SY5Y cells transfected with constructs expressing GFP (Control-GFP) or A53T--
synuclein-GFP (-synA53T-GFP) immunocytochemically stained for -synuclein protein at 
24h, scale bar = 10μm; quantification of this expression is shown in (f). (g) Total neurite length 
and (h) representative images of transfected SH-SY5Y cells expressing either control-GFP, -
synWT-GFP or -synA53T-GFP and cultured with or without 50ng/ml rhBMP2 for 72h. Scale 
bar = 50μm. All data are presented as mean ± SEM from at least three experiments. (* p < 0.05, 
p < 0.01, p < 0.001 vs. control or as indicated. One-way ANOVA with Tukey’s (a, b, c, g) or 
Dunnett’s (f) post hoc test).  
 
  
 
Figure 3: rhBMP2 promotes neurite growth and partially protects against mDA neuron 
loss in MPP+-treated and 6-OHDA-treated primary cultures of rat VM.    
Total neurite length of DA neurons in E14 VM cultures following 72h treatment with (a) 6-
OHDA or (b) MPP+, at the concentrations indicated. (c) Total neurite length and (d) 
representative photomicrographs of dopaminergic neurons in E14 VM cultures treated with 
50ng/ml rhBMP2 and cultured with or without 5µM MPP+ or 5μM 6-OHDA for 72 h. Scale 
bar = 50μm. (e) Somal area, (f) TH+ neurons as a percentage of total cells and (g) number of 
cells per field of view, in primary cultures of the E14 rat VM treated with 50ng/ml rhBMP2 
and cultured with or without 5μM MPP+ or 5μM 6-OHDA for 72h. (h) Representative 
photomicrographs of TH/DAPI-stained E14 VM cultures, treated as indicated. Scale bar = 
50µm. All data are presented as mean ± SEM from at least three experiments. (* p < 0.05, p < 
0.01, p < 0.001 vs. control or as indicated. One-way ANOVA with Tukey’s post hoc test). 
 
 
 
 
 
 
 
 
 
Figure 4: rhBMP2 promotes neurite growth in wild-type -synuclein- and A53T -
synuclein-overexpressing cells in primary cultures of E14 rat VM.    
(a) Representative images of primary cultures of E14 rat VM transfected with constructs 
expressing GFP (Control-GFP),  -synucleinWT-GFP (-synWT-GFP) or -synuclein A53T-
GFP (-synA53T-GFP), then immunocytochemically stained for -synuclein at 72h. Scale bar 
= 10μm. Quantification of (b) -synuclein expression and (c) cell somal area in cultures 
transfected with Control-GFP, -synWT-GFP and -synA53T-GFP. (d) Representative 
images (Scale bar = 50μm) and (e) quantification of total neurite length of E14 VM cultures 
transfected with Control-GFP, -synWT-GFP and -synA53T-GFP and cultured with or 
without 50ng/ml rhBMP2 for 72h. All data are presented as mean ± SEM from at least three 
experiments. (*** p < 0.001 vs. control or as indicated. One-way ANOVA with Tukey’s post 
hoc test). 
 
 
 
 
 
 
 
 
 
